Biomerica shares surge 11.12% intraday after CMS sets $300 Medicare payment rate for InFoods IBS test.

Biomerica surged 11.12% intraday trading, driven by CMS's final pricing decision for the InFoods IBS test, which set a $300 national Medicare payment rate effective January 1, 2026. The rate, impacting the company's core revenue, follows Medicare's role as the largest U.S. healthcare payer covering over 20% of adults and a significant portion of IBS patients. Biomerica specializes in advanced diagnostic solutions, including the InFoods IBS test for irritable bowel syndrome detection.